Abstract
In this chapter the current knowledge, as well as the challenges around the drug metabolism and pharmacokinetics (DMPK)-associated concerns in streamlining drug research and therapeutic use of Ranunculales phytometabolites are highlighted. Data from various in vivo and in vitro models are classified and discussed. DMPK characteristics of Ranunculales phytometabolites are summarized and presented according to the phylogenetic relationship of families and genera. This chapter also presents an overview of the complex interaction between DM enzymes/transporters and phytochemicals, as well as of the most advanced approaches in the relevant field. Since species-specific differences in DMPK exist, data obtained from animal studies may not be sufficient to predict DM reactions in humans. Omics-based methodologies (genomics, epigenomics, transcriptomics, proteomics, microbiomics, and metabolomics) should be used to enhance the reliability of DMPK prediction. The fluorescent probes may bridge the gap between conventional models and in vivo clinical studies in humans and provide a consistent basis for DMPK assay development.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
